4.2 Article

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 18, Issue 11, Pages 1727-1733

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2012.06.014

Keywords

Graft-versus-host disease; Graft-versus-leukemia effect; Reduced-intensity conditioning

Funding

  1. Public Health Service grant from the National Cancer Institute, the National Heart Lung and Blood Institute, the National Institute of Allergy and Infectious Diseases
  2. Health Services and Resource Administration [HHSH234200637015C]

Ask authors/readers for more resources

We studied graft-versus-host disease (GVHD) on relapse, transplant-related mortality (TRM), disease-free survival (DFS), and overall survival (OS) after allogeneic transplantation for acute myelogenous leukemia (AML) (n = 4224) and myelodysplastic syndrome (MDS) (n = 1517) in 4 groups: without GVHD, acute GVHD (aGVHD) alone, chronic GVHD (cGVHD) alone, and aGVHD + cGVHD. Examining GVHD as a time-dependent covariate, after myeloablative conditioning (MAC), cGVHD and aGVHD + cGVHD were associated with lower relapse (P <.002). TRM was higher in all GVHD groups (P <.0001); DFS and OS were lower with aGVHD +/- cGVHD (P <.0001). After reduced-intensity conditioning (RIC), relapse was lower in all GVHD groups (P <.0001); TRM was increased and DFS and OS were reduced with any GVHD (P <.0001). In those surviving disease-free (>= 1-year) after MAC, relapse risks were similar in all groups and TRM was higher with any GVHD (P <.0001). DFS and OS were lower with cGVHD and aGVHD + cGVHD (P < .0006). After RIC, relapse was lower (P = .009) and TRM higher (P = .002) only with aGVHD + cGVHD. DFS was similar in all groups and OS worse with aGVHD + cGVHD. After MAC, GVHD has an adverse effect on TRM with early modest augmentation of GVHD-associated graft-versus-leukemia (GVL). With RIC, GVHD-associated GVL may be important in limiting both early and late leukemia recurrence. Biol Blood Marrow Transplant 18: 1727-1733 (2012) (C) 2012 American Society for Blood and Marrow Transplantation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available